10-K: MIRA Pharmaceuticals Files 10-K, Details Capital Structure and Development Programs

MIRA Pharmaceuticals' 10-K filing outlines its capital structure, governance, and the development status of its neuroscience programs, including Ketamir-2 and MIRA-55.

Summary

• MIRA Pharmaceuticals, a pre-clinical stage company, has filed its annual report on Form 10-K.
• The company's authorized capital stock consists of 100,000,000 shares of common stock and 10,000,000 shares of preferred stock, both with a par value of $0.0001 per share.
• The board of directors is authorized to issue preferred stock without shareholder approval, which could potentially impact common stock rights.
• MIRA is developing Ketamir-2, an oral ketamine analog for treatment-resistant depression and major depressive disorder with suicidal ideation, and MIRA-55, an oral pharmaceutical marijuana molecule for neuropathic pain, anxiety, and cognitive decline.
• The DEA has determined that Ketamir-2 is not a controlled substance, and the company has submitted paperwork for MIRA-55 to be evaluated.
• The company anticipates submitting an IND for Ketamir-2 by the end of 2024 and for MIRA-55 for the treatment of elderly patients suffering from anxiety with some cognitive decline by the end of the second quarter of 2025.
• IQVIA estimates the U.S. market for Ketamir-2 could reach $3 billion in peak annual net sales, with a base case eNPV of around $92 million.
• The U.S. CNS market, where MIRA-55 will compete, is estimated to be worth $48 billion by 2027.
• The company has completed several pre-clinical studies of MIRA-55, including tests for anxiety, pain, and cognition.
• MIRA-55 has shown a 30-fold increased CB2 activation compared to CBD in animal studies.
• The company has a pending provisional patent application for MIRA-55 and a U.S. patent for MIRA1a, though it does not plan to develop MIRA1a at this time.
• As of March 28, 2024, the company had three employees and various consultants providing support.
• The company has an accumulated deficit of $21.3 million through December 31, 2023, and $9.3 million through December 31, 2022.
• The company's independent auditor has included an explanatory paragraph in their report relating to the company's ability to continue as a going concern.
• As of March 28, 2024, there were 14,780,885 shares of common stock issued and outstanding.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are promising aspects regarding the company's drug development programs and market potential, the significant financial challenges and going concern warning temper the overall sentiment. The company's reliance on external funding and the inherent risks of drug development contribute to a cautious outlook.

Positives

• Ketamir-2 has been determined by the DEA to not be a controlled substance, potentially simplifying its regulatory path.
• MIRA-55 has shown promising pre-clinical results, including a 30-fold increase in CB2 activation compared to CBD.
• The company has a clear clinical development plan for both Ketamir-2 and MIRA-55.
• IQVIA estimates a significant market opportunity for Ketamir-2, with potential peak annual sales of $3 billion.
• MIRA-55 has demonstrated the ability to rapidly and significantly improve cognitive performance with acute use, doubling cognitive performance after a single dose in normal mice.

Negatives

• The company has a limited operating history and has incurred significant losses since its inception.
• The company's independent auditor has raised substantial doubt about its ability to continue as a going concern.
• The company is dependent on the success of its product candidates, which may not receive regulatory approval or be successfully commercialized.
• The company will need additional funds to complete the further development of its business plan.
• Certain executive officers are not employed on a full-time basis.
• The company faces intense competition from other pharmaceutical and biotechnology companies.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing.
• The company's product candidates may not receive regulatory approval or be successfully commercialized.
• The company faces risks related to health, pandemics, and epidemics that could disrupt its operations.
• Results of pre-clinical studies and early clinical trials are not necessarily predictive of future results.
• The company may fail to expand its manufacturing capability in time to meet market demand.
• The company relies on third parties to conduct clinical trials and manufacture its product supplies.
• The company may be unable to obtain and maintain intellectual property protection for its technology and products.
• The company's securities may experience rapid and substantial price volatility.
• The company is subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws.
• The company's proprietary information may be lost or it may suffer security breaches.
• The company is subject to federal and state healthcare laws and regulations.
• The company may acquire other companies which could divert management's attention and disrupt operations.
• The company may be unable to achieve expected market acceptance for its products.
• The company may face intense competition from companies with greater resources and experience.
• Product shipment delays could have a material adverse effect on the company's business.
• The DEA could change its position on the classification of Ketamir-2 and MIRA-55.
• The company's manufacturing processes are complex and uncertain.
• The company may be subject to product liability lawsuits.
• Counterfeit versions of the company's products could harm its business.
• The company depends on key personnel and its ability to attract and retain employees.
• The company's employees may engage in misconduct or other improper activities.
• The company's operating results may vary significantly in future periods.
• The company has yet to generate revenues or achieve a profit and may not for many years, if at all.
• Conflicts of interest may arise between the company and MIRALOGX.
• The company's future viability will largely depend on the positive development of Ketamir-2 and MIRA-55.
• The company has limited marketing experience and may not be able to successfully commercialize its product candidates.
• The company will need to further increase the size and complexity of its organization in the future.
• The company's product candidates, if approved, may be unable to achieve the expected market acceptance.
• If the price for any future approved products decreases or if government and other third-party payers do not provide coverage and adequate reimbursement levels, the company's revenue and prospects for profitability will suffer.
• The company expects to face intense competition, often from companies with greater resources and experience than it has.
• The company is dependent on a limited number of suppliers for materials and components required to manufacture its product candidates.
• The company maintains its cash at financial institutions, at times in balances that exceed federally insured limits.
• The company relies on third parties to conduct clinical trials for its product candidates.
• The company relies on third parties to manufacture its clinical product supplies and clinical candidates.
• The company's proprietary information, or that of its suppliers and business partners, may be lost or it may suffer security breaches.
• Failure of the company's information technology systems, including cybersecurity attacks or other data security incidents, could significantly disrupt the operation of its business.
• Legislative or regulatory reform of the health care system in the U.S. may affect the company's ability to profitably sell its products, if approved.
• The company may acquire other companies which could divert management's attention, result in additional dilution to its shareholders and otherwise disrupt its operations and harm its operating results.
• Clinical trials for the company's product candidates are expensive, time-consuming, uncertain, and susceptible to change, delay or termination.
• Clinical trials of synthetic cannabinoid drug candidates and ketamine analogs are novel with very limited or non-existing history.
• Any failure by the company to comply with existing regulations could harm its reputation and operating results.
• The company is subject to federal and state healthcare laws and regulations.
• The regulatory approval processes with the FDA are lengthy and inherently unpredictable.
• There is a high rate of failure for drug candidates proceeding through clinical trials.
• If the company is found in violation of federal or state fraud and abuse laws, it may be required to pay a penalty and/or be suspended from participation in federal or state health care programs.
• Serious adverse events or other safety risks could require the company to abandon development and preclude, delay or limit approval of its product candidates.
• The company's existing collaboration arrangements and any that it may enter into in the future may not be successful.
• The company is dependent on its current and future product candidates, some of which may not receive regulatory approval or be successfully commercialized.
• The company may not be able to adequately protect its product candidates or its proprietary technology in the marketplace.
• If the company is unable to obtain and maintain intellectual property protection for its technology and products, or if the scope of the intellectual property protection obtained is not sufficiently broad, its competitors could commercialize technology and products similar or identical to its, and its ability to successfully commercialize its technology and products may be impaired.
• If third parties claim that the company's intellectual property, products, processes, or anything else used by it infringes upon their intellectual property, its operating profits could be adversely affected.
• The company has no patent protection for MIRA-55, which could adversely impact MIRA-55s potential competitive position.
• Because of the speculative nature of investment risk, you may lose your entire investment.
• Certain of the company's founding stockholders, plus its existing officers and directors, control a substantial interest in it and thus may influence certain actions requiring stockholder vote.
• Sales of a significant number of shares of the company's common stock in the public markets, or the perception that such sales could occur, could depress the market price of its common stock.
• The requirements of being a public company may strain the company's resources, divert management's attention and affect its ability to attract and retain executive management and qualified board members.
• The company is an emerging growth company, and any decision on its part to comply only with certain reduced reporting and disclosure requirements applicable to emerging growth companies could make shares of its common stock less attractive to investors.
• If the company fails to maintain compliance with Nasdaq Listing Rules, its shares may be delisted from Nasdaq, which would result in a limited trading market for its shares and make obtaining future debt or equity financing more difficult for the company.
• Some provisions of Florida law and the company's amended and restated articles of incorporation and amended and restated bylaws may have anti-takeover effects that could discourage an acquisition of the company by others, even if an acquisition would be beneficial to its shareholders and may prevent attempts by its shareholders to replace or remove its current management.
• The company's amended and restated bylaws designates the state courts located within the state of Florida as the exclusive forum for substantially all disputes between the company and its shareholders and the federal district courts as the exclusive forum for Securities Act claims, which could limit its shareholders ability to obtain a favorable judicial forum for disputes with the company.
• Securities or industry analysts may not regularly publish reports on the company, which could cause the price of its securities or trading volumes to decline.
• The company will likely conduct further offerings of its equity securities in the future, in which case your proportionate interest may become diluted.
• The company may issue shares of preferred stock in the future, which could make it difficult for another company to acquire it or could otherwise adversely affect holders of its common stock, which could depress the price of its common stock.
• The company has never declared or paid any cash dividends or distributions on its capital stock and does not anticipate paying any cash dividends on its common stock in the foreseeable future.

Future Outlook

The company expects to continue to incur significant losses into the foreseeable future and will require additional funding to support its operations and development activities. The company anticipates submitting an IND for Ketamir-2 by the end of 2024 and for MIRA-55 for the treatment of elderly patients suffering from anxiety with some cognitive decline by the end of the second quarter of 2025.

Management Comments

• Management believes that the Company has sufficient resources available to support its development activities and business operations and timely satisfy its obligations as they become due into the fourth quarter of 2024.
• Management plans to secure additional capital, potentially through a combination of public or private equity offerings and strategic transactions, including potential alliances and drug product collaborations.

Industry Context

The company operates in the competitive pharmaceutical and biotechnology industries, facing competition from both established companies and emerging startups. The development of novel treatments for neurological and neuropsychiatric disorders is a growing area of focus, with significant unmet medical needs.

Comparison to Industry Standards

• The company's reliance on third-party manufacturers and CROs is common in the biotech industry, particularly for pre-clinical stage companies.
• The company's focus on developing novel compounds with improved properties compared to existing treatments is a common strategy in the pharmaceutical industry.
• The company's financial situation, with significant losses and reliance on external funding, is typical for early-stage biotech companies.
• The company's estimated market opportunity for Ketamir-2 is comparable to other novel antidepressants in development.
• The company's pre-clinical testing of MIRA-55, including tests for anxiety, pain, and cognition, is consistent with industry standards for drug development.

Management Changes

Corporate Governance

Related Party Transactions

• The company has a line of credit and promissory note with the Bay Shore Trust, a related party.
• The company has an exclusive license agreement with MIRALOGX, LLC, a related party.
• The company has an agreement for shared lease costs with MIRALOGX, LLC, a related party.
• The company has a consulting agreement with Dr. Chris Chapman, a former executive officer and director.
• The company has a consulting relationship with Adam Kaplin, a former executive officer.

Stakeholder Impact

• Shareholders face the risk of potential loss of investment due to the company's financial challenges and the speculative nature of drug development.
• Employees may experience uncertainty due to the company's financial situation and potential restructuring.
• Customers (potential patients) may benefit from the development of new treatments for neurological and neuropsychiatric disorders.
• Suppliers and creditors face the risk of non-payment due to the company's financial challenges.
• The company's success will depend on its ability to obtain regulatory approval and commercialize its product candidates, which will impact all stakeholders.

Next Steps

• The company plans to submit an IND for Ketamir-2 by the end of 2024.
• The company plans to submit an IND for MIRA-55 for the treatment of elderly patients suffering from anxiety with some cognitive decline by the end of the second quarter of 2025.
• The company will continue pre-clinical development of MIRA-55 across a range of CNS diseases.
• The company will explore strategic collaborations to maximize the value of its product candidates.
• The company will conduct several other pre-clinical studies and initiate a 7-day maximum tolerated dose study of MIRA-55 in rats and dogs.

Key Dates

Keywords

Ketamir-2, MIRA-55, pharmaceutical, neuroscience, depression, neuropathic pain, cannabinoid, clinical trials, FDA, biotechnology, intellectual property, drug development, pre-clinical, CNS, anxiety, dementia